Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
3.470
+0.020 (0.58%)
At close: Jul 24, 2026, 4:00 PM EDT
3.490
+0.020 (0.58%)
After-hours: Jul 24, 2026, 7:35 PM EDT
Galectin Therapeutics Employees
Galectin Therapeutics had 9 employees as of December 31, 2025. The number of employees decreased by 6 or -40.00% compared to the previous year.
Employees
9
Change (1Y)
-6
Growth (1Y)
-40.00%
Revenue / Employee
n/a
Profits / Employee
-$2,937,333
Market Cap
228.52M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 9 | -6 | -40.00% |
| Dec 31, 2024 | 15 | 1 | 7.14% |
| Dec 31, 2023 | 14 | 2 | 16.67% |
| Dec 31, 2022 | 12 | 3 | 33.33% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Coherus Oncology | 145 |
| Adagene | 128 |
| Nautilus Biotechnology | 127 |
| AC Immune | 122 |
| Orchestra BioMed Holdings | 86 |
| Cartesian Therapeutics | 75 |
| Compugen | 75 |
GALT News
- 4 weeks ago - Galectin Therapeutics reaches alignment with FDA on belapectin pathway - TheFly
- 4 weeks ago - Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - GlobeNewsWire
- 2 months ago - Galectin Therapeutics presents belapectin data at EASL 2026 - TheFly
- 2 months ago - Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis - GlobeNewsWire
- 2 months ago - Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Galectin Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - Galectin Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Galectin Therapeutics publishes NAVIGATE Phase 2b trial results - TheFly